

Join us!

AstraZeneca satellite symposium at

ESMO Gastrointestinal Cancers Congress 2024 Industry Satellite Symposium

Do not miss the ESMO Gastrointestinal Cancers Congress 2024 Industry Satellite Symposium 'Gastric / gastroesophageal junction cancer treatment landscape: advancements, challenges and future prospects', organised and funded by AstraZeneca.

Please join us for valuable insights from our expert faculty, Dr Hanneke Van Laarhoven (Chair, Netherlands), Dr Shannon Chan (Hong Kong) and Dr Alexander Quaas (Germany), on the recent advancements, unmet need, and the future therapeutic outlook for the treatment of early and advanced gastric / gastroesophageal junction cancer.

Gastric / gastroesophageal junction cancer treatment landscape: advancements, challenges and future prospects

Thursday, 27 June 2024 | 12:45–13:45 CEST

Room 13a, ICM – International Congress Center of the Munich Messe, Munich, Germany

Time (CEST) PROGRAMME

12:45–12:50 **Welcome and introductions**
Hanneke Van Laarhoven



Hanneke Van Laarhoven*,
MD, PhD

University of Amsterdam,
Amsterdam, Netherlands

12:50–13:05 **Advancements and unmet needs in treating early and advanced GC / GEJC**
Shannon Chan



Shannon Chan, FRCSEd, FHKAM

The Chinese University of Hong
Kong, Hong Kong

13:05–13:20 **Evolving treatment landscape for early and advanced GC / GEJC**
Hanneke Van Laarhoven

13:20–13:45 **Panel discussion on opportunities and challenges in treatment selection and biomarker testing for GC / GEJC**

Alexander Quaas
All faculty participation



Alexander Quaas, MD, PhD

University Hospital of Cologne,
Cologne, Germany

Audience Q&A

All faculty and audience participation

We look forward to seeing you in Munich!

This scientific exchange symposium is organised and funded by AstraZeneca for healthcare professionals only.

The symposium will be 60 minutes and will include panel discussions with audience participation and an audience Q&A.

During this symposium, data may refer to medicines or indications under investigation or that may not be approved in your country. The information should under no circumstances be regarded as a recommendation for use of the medicine or indication. Please consult your local prescribing information.

*Image captured by Marlou Pulles.

Veeva ID: DE-69242

Date of preparation: April 2024